FDA Places Partial Hold on Biohaven’s BHV-7000 Epilepsy Studies
The FDA has paused new patient enrollment in Biohaven’s BHV-7000 epilepsy studies after rodent findings. Dosing continues for current participants.
/ 13 items
#BHVN↓
SK Biopharmaceuticals Licenses Biohaven’s Kv7 Platform in Deal Worth Up to $795 Million
SK Biopharm gains exclusive worldwide rights to Biohaven’s opakalim and Kv7 platform in a deal worth up to $795M, with a possible 2029 U.S. launch.
BofA Downgrades Biohaven to Underperform, Cuts Price Target to $11 on Kv7 Risks
Analyst highlights competition risk in Kv7 epilepsy program and cuts peak sales forecast.
Biohaven Shares Surge as New Drugs Deliver Breakthrough Results in Graves’ Disease and IgA Nephropathy
Biohaven shares rose after strong early results from 2 drugs that quickly lower harmful antibodies in autoimmune diseases.
Analysts Turn Bullish on Biohaven, Caris, and Veracyte
Canaccord says Biohaven is undervalued and could rise on epilepsy trial results. Jefferies likes Caris Life Sciences and Veracyte, citing strong growth in cancer diagnostics and solid finances.
Goldman Sachs Starts Coverage on Biohaven with Buy Rating
Goldman Sachs initiates coverage on Biohaven with a Buy rating and $23 price target, highlighting BHV-1400 and its potential in the large IgA nephropathy market.